Sandoz Sues Amgen Over Patents
This is a the United States news story, published by Yahoo Finance, that relates primarily to Amgen news.
the United States news
For more the United States news, you can click here:
more the United States newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
generic drug manufacturer Sandoz. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest patents news, Amgen news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
antitrust lawsuitReuters
•Health
Health
Sandoz files U.S. antitrust lawsuit against Amgen over arthritis drug

77% Informative
Swiss generic drug manufacturer Sandoz says it has filed an antitrust lawsuit against Amgen .
Sandoz alleges Amgen blocked competition from more cost-effective biosimilar competitors.
Amgen did not immediately reply to a request for comment.
In 2024 , Enbrel generated $3.3 billion in revenue in the United States .
VR Score
84
Informative language
90
Neutral language
45
Article tone
formal
Language
English
Language complexity
73
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links